Cardiac Amyloidosis Foundations-Treatment of Transthyretin Cardiac Amyloidosis

Video Transcription

Video Summary

The speaker discusses the treatment of transthyretin cardiac amyloidosis. They provide an overview of traditional heart failure guideline-directed therapy, focusing on its limitations for treating patients with cardiac amyloid. They also discuss the management of arrhythmias in these patients. The speaker then dives into specific treatments for transthyretin amyloidosis, including TTR stabilizers and the use of digoxin, beta blockers, ACE inhibitors, and MRAs. They highlight the limited data on the effectiveness of these medications and provide recommendations for their use. The speaker also discusses the use of SGLT2 inhibitors and the potential benefits of ICDs for preventing sudden cardiac death in cardiac amyloidosis patients. They then move on to targeted therapies for transthyretin amyloidosis, including TTR stabilizers, TTR suppression with silencers and antisense oligonucleotides, CRISPR-Cas9 gene editing, and novel approaches for oligomer disruption and amyloid degradation. The speaker acknowledges the need for more research in these areas and highlights the challenges posed by the high cost of these therapies. They stress the importance of a multidisciplinary approach to managing cardiac amyloidosis and offer their availability for any questions.

Keywords

transthyretin cardiac amyloidosis

heart failure therapy

arrhythmia management

TTR stabilizers

SGLT2 inhibitors

ICDs

CRISPR-Cas9